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INTRODUCTION 
Ovarian	cancers	have	the	highest	fatality	rate	among	gyne-
cologic	malignancies.	The	disease	is	identified	in	advanced	
stages	in	most	patients	and	only	one	out	of	three	cases	has	
a	chance	of	long-term	survival	[1].	The	lack	of	specific	symp-
toms	in	addition	with	the	lack	of	reliable	screening	tests	cause	
a	delay	in	diagnosis,	resulting	in	low	survival	rates.	While	the	
overall	5-year	survival	rate	is	44%,	it	is	89%	for	localized	dis-
ease,	36%	for	regional	metastasis,	and	17%	for	distant	metas-
tasis	[2].	
Transvaginal	ultrasonography	has	a	high	false-positive	rate	
and	leads	to	unnecessary	surgical	procedures	[3].	Frequent	
positivity	of	CA-125	in	women	with	different	benign	diseases	
limits	the	efficacy	of	screening	[4].	Although	the	sensitivity	
and	specificity	of	CA-125	can	be	increased	by	combining	it	
with	ultrasonography,	the	predictive	level	remains	still	rela-
tively	low.	The	positive	predictive	value	for	invasive	cancer	is	
3.7%	for	an	abnormal	CA-125,	1.0%	for	an	abnormal	transvagi-
nal	ultrasonography,	and	23.5%	if	both	tests	are	abnormal	[5].	
For	this	reason,	determination	of	serum	identifiers	that	can	be	
used	independently	or	in	combination	with	CA-125	and/or	
Original Article
Thrombopoietin: a novel candidate tumor marker for 
the diagnosis of ovarian cancer
Timucin Mermer
1, Mustafa Cosan Terek
1, Burak Zeybek
1, Ahmet Mete Ergenoglu
1, Ahmet Ozgur Yeniel
1, 
Aydın Ozsaran
1, Osman Zekioglu
2
Departments of 
1Obstetrics and Gynecology and 
2Pathology, Ege University School of Medicine, Izmir, Turkey
Received May 23, 2011, Revised Nov 16, 2011, Accepted Nov 25, 2011
Correspondence to Burak Zeybek
Department of Obstetrics and Gynecology, Ege University School of 
Medicine, Bornova, 35100, Izmir, Turkey. Tel: 90-232-390-1700, Fax: 90-232-
390-0743, E-mail: burak.zeybek@ege.edu.tr
pISSN 2005-0380 
eISSN 2005-0399
Copyright © 2012. Asian Society of Gynecologic Oncology, Korean Society of Gynecologic Oncology 
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License 
(http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and 
reproduction in any medium, provided the original work is properly cited.
www.ejgo.org
Objective:	To	investigate	the	decisive	role	of	preoperative	serum	thrombopoietin	levels	in	the	discrimination	of	benign	and	
malignant	ovarian	pathologies	and	its	value	in	the	evaluation	of	treatment	response.
Methods: Fifty	patients	with	diagnoses	of	adnexal	masses	(25	benign,	25	malignant)	were	included	in	the	study.	Blood	samples	
were	collected	from	all	cases	preoperatively.	Age,	menopausal	status,	adnexal	mass	size,	preoperative	CA-125	level,	platelet	
count,	the	stage	of	the	disease	(FIGO	stage),	tumor	grade,	histologic	subgroup,	the	residual	tumor	mass,	ascites	cytology,	
surgical	procedures,	and	postoperative	treatments	were	recorded	for	the	malignant	group.	Response	to	treatment	was	
evaluated	based	on	the	revised	RECIST	guideline.	
Results: The	preoperative	serum	thrombopoietin	levels	of	the	malignant	cases	(median,	98;	range,	7	to	768)	were	significantly	
higher	when	compared	with	those	of	benign	cases	(median,	27;	range,	13	to	131;	p=0.004).	The	positive	predictive	value	
of	CA-125	was	found	to	be	79%,	when	it	was	used	as	a	single	marker;	however	it	had	risen	to	85%	when	both	CA-125	and	
thrombopoietin	levels	were	used.	There	was	no	significant	relationship	between	preoperative	serum	thrombopoietin	levels	and	
tumor	grade,	ascites	cytology,	presence	of	residual	mass,	and	response	to	treatment.	The	preoperative	serum	thrombopoietin	
levels	were	significantly	higher	in	stage	III-IV	cases	and	cases	with	serous	histology.	The	post-treatment	serum	thrombopoietin	
levels	in	the	malignant	group	were	significantly	lower	as	compared	with	the	preoperative	thrombopoietin	levels.	
Conclusion: Thrombopoietin	can	play	an	additive	role	for	prediction	of	ovarian	cancer.	
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transvaginal	ultrasonography	has	a	critical	significance.	
Gene	expression	analysis,	proteomics,	and	new	tumor	mark-
ers	are	among	the	current	alternatives	of	early	tumor	detec-
tion	[6,7].	A	novel	candidate	marker,	thrombopoietin,	which	
is	known	as	a	primary	regulator	protein,	regulates	platelet	
production	as	well	as	the	megakaryopoiesis	process.	Throm-
bopoietin	demonstrates	its	effect	by	binding	to	receptor	
c-Mpl,	a	cellular	proto-oncogene	product	[8].	In	the	literature	
during	the	last	decade,	there	are	case	reports	associated	with	
the	following	three	types	of	malignant	tumors	that	have	been	
shown	to	secrete	thrombopoietin:	Ovarian	cancer,	hepato-
blastoma,	and	hepatocellular	carcinoma	[9-11].	
In	the	present	study,	the	decisive	role	of	preoperative	serum	
thrombopoietin	levels	in	the	discrimination	of	benign	and	
malignant	ovarian	pathologies	and	its	value	in	the	evaluation	
of	treatment	response	have	been	investigated.
MATERIALS AND METHODS
Between	January	2008	and	April	2010,	50	patients	with	di-
agnoses	of	adnexal	masses	and	hospitalized	for	surgery	in	
the	Department	of	Obstetrics	and	Gynecology,	Ege	University	
Hospital	were	included	in	the	study.	Blood	samples	were	col-
lected	from	all	cases	on	the	same	day	of	surgery	just	after	the	
induction	of	anesthesia.	Cases	with	non-ovarian	originating	
adnexal	masses,	and	patients	with	inflammatory	conditions,	
such	as	allergies	or	infections,	were	not	included	in	the	study.	
Informed	consent	of	all	cases	were	obtained	and	the	study	
was	approved	by	the	Ege	University	Hospital	Ethics	Commit-
tee.	The	cases	included	in	the	study	were	divided	into	two	
groups	(25	malignant	and	25	benign	cases)	based	on	postop-
erative	ovarian	pathology	results.	
The	patients	with	ovarian	cancer	underwent	cytoreductive	
surgery	comprised	of	removal	of	adnexial	mass,	hysterectomy,	
total	omentectomy	and	retroperitoneal	debulking	followed	
by	adjuvant	paclitaxel	and	carboplatin	chemotherapy.
In	this	prospective	case-control	study,	age,	menopausal	
status,	adnexal	mass	size,	preoperative	CA-125	level,	platelet	
count,	the	stage	of	the	disease,	tumor	grade,	histologic	sub-
group,	the	residual	tumor	mass,	ascites	cytology,	surgical	pro-
cedures,	and	postoperative	treatments	were	recorded	for	the	
malignant	group.	The	FIGO	stage	was	identified	based	on	the	
surgery	and	pathology	results.	The	pathologic	analyses	of	all	
the	cases	included	in	the	study	were	performed	by	an	experi-
enced	gynecologic	pathologist	and	tumors	with	a	low	poten-
tial	of	malignancy	were	not	included	in	the	study.	Response	to	
treatment	was	evaluated	based	on	the	revised	RECIST	guide-
line	[12].	Blood	was	collected	once	more	from	the	patients	in-
cluded	in	the	malignant	study	group	6	weeks	after	treatment	
in	order	to	re-analyze	serum	thrombopoietin	levels.	The	serum	
samples	were	waited	for	30	minutes	and	centrifuged	at	2,000	
g	for	10	minutes	and	stored	at	-80
oC	until	the	analysis.	
Serum	thrombopoietin	levels	were	analyzed	with	a	throm-
bopoietin-immunoassay	kit	(R&D	Systems,	Minneapolis,	MN,	
USA)	in	accordance	with	the	manufacturer’s	manual.	The	sen-
sitivity	of	thrombopoietin	ELISA	was	15.7	pg/mL.	
SPSS	ver.	15.0	(SPSS	Inc.,	Chicago,	IL,	USA)	was	used	for	statis-
tical	analysis	of	data	in	our	study.	The	comparisons	in	line	with	
the	specifications	of	the	variables	were	made	using	a	t-test,	
chi-square	test,	Mann-Whitney	U-test,	and	Spearman’s	rho	test.	
The	calculation	sensitivity	and	specificity	of	serum	thrombo-
poietin	and	CA-125	in	the	determination	of	malignancy	was	
performed	using	logistic	regression	analysis	and	receiver	op-
erating	characteristic	(ROC)	curve	analysis.	A	value	of	p<0.05	
was	considered	statistically	significant.	
RESULTS
The	clinical	characteristics	of	patients	and	the	number	of	pa-
tients	with	CA-125	and/or	thrombopoietin	positivity	are	sum-
marized	in	Tables	1	and	2,	respectively.	The	preoperative	se-
rum	thrombopoietin	levels	of	the	malignant	cases	(median,	98	
pg/mL;	range,	7	to	768	pg/mL)	were	significantly	higher	when	
compared	with	those	of	benign	cases	(median,	27	pg/mL;	
range,	13	to	131	pg/mL;	p=0.004).	As	expected,	the	preopera-
tive	serum	CA-125	levels	in	the	malignant	group	(median,	344	
Table 1. Clinical characteristics of patients
Characteristics
Menopause 
(n)
Age  
(yr)
Mass size 
(cm, mean±SD)
Preoperative 
thrombopoietin levels  
(pg/mL, median)
Preoperative  
CA-125 levels  
(U/mL, median)
Preoperative  
platelet count
Malignant group (n=25) 20 56.44 9.4±4.0 98 344 275,000
Benign group (n=25) 20 56.64 8.1±3.5 27 19 278,000
p-value 0.95 0.26 0.004 0.0008 0.90
p<0.05, statistically significant.Timucin Mermer, et al.
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U/mL;	range,	10	to	4,587	U/mL)	were	also	significantly	higher	
as	compared	with	the	benign	group	(median,	19	U/mL;	range,	
3	to	303	U/mL;	p=0.0008).	
A	comparison	of	preoperative	serum	thrombopoietin	levels	
in	patients	with	invasive	ovarian	cancer	and	certain	character-
istic	features	that	are	considered	to	have	prognostic	signifi-
cance	is	provided	in	Table	3.	The	malignant	cases	were	staged	
between	1	and	4	based	on	the	severity	of	the	disease	accord-
ing	to	the	FIGO	classification.	According	to	surgical	staging,	4	
cases	were	stage	I,	7	cases	were	stage	II,	12	cases	were	stage	
III,	and	2	cases	were	stage	IV.	It	has	not	been	possible	to	show	
a	significant	relationship	between	preoperative	serum	throm-
bopoietin	levels	and	tumor	grade,	ascites	cytology,	presence	
of	residual	mass,	and	response	to	treatment.	On	the	other	
hand,	the	relationship	between	the	FIGO	stage	and	histologic	
subgroup	and	preoperative	serum	thrombopoietin	levels	
were	significant.	Out	of	11	stage	(I-II)	patients	in	the	malig-
nant	group,	4	patients	had	serous	histology	while	7	had	non-
serous.	Out	of	14	stage	(III-IV)	patients	in	the	malignant	group,	
10	patients	had	serous	histology	while	4	patients	had	non-
serous	histology.	The	preoperative	serum	thrombopoietin	lev-
els	were	significantly	higher	in	stage	III-IV	cases	and	cases	with	
serous	histology	(Table	3).	
The	utility	of	preoperative	serum	thrombopoietin	levels	for	
predicting	malignancy,	sensitivity	and	specificity	calculations	
were	performed	(Table	4).	In	all	the	cases,	when	the	preopera-
tive	serum	thrombopoietin	cut-off	level	was	taken	as	90	pg/
mL	to	identify	malignancy,	the	sensitivity	was	52%,	the	speci-
ficity	was	84%,	the	positive	predictive	value	(PPV)	was	76%,	
and	the	negative	predictive	value	(NPV)	was	63%.	In	all	the	
Table 2. Number of patients with CA-125 and/or thrombopoietin positivity and/or negativity
Patients  
CA-125 (+)  
thrombopoietin (+)
CA-125 (+)  
thrombopoietin (-)
CA-125 (-)  
thrombopoietin (+)
CA-125 (-)  
thrombopoietin (-)
Benign group (n=25) 2 4 2 17
Malignant group (n=25) 12 11 1 1
Table 3. The relationship of prognostic factors with thrombopoietin (pg/mL) levels in cases of ovarian cancer
Valiables No. Mean Median Range p-value
Age ≤50 7 161 98 29-494 0.650
>50 18 157 94 6-768
Stage  I-II 11 64 58 6-148 0.017
III-IV 14 233 127 12-768
Grade  1-2 9 206 120 6-768 0.571
3 16 132 73 12-484
Histology  Serous 14 235 127 26-768 0.008
Non-serous 11 61 36 6-148
Ascites cytology Malign 14 218 125 21-248 0.139
Benign 11 83 71 6-768
Residual mass  Yes 12 236 116 12-768 0.165
No 13 87 71 6-248
Treatment response  Yes 11 238 123 12-768 0.110
No  14 97 75 6-324
Table 4. Additive role of thrombopoietin for ovarian cancer prediction
Sensitivity Specificity Positive predictive value Negative predictive value
CA-125 92 76 79 90
Thrombopoietin 52 84 76 63
CA-125+thrombopoietin 92.3 89 85 94.4
Values are presented as percentage (%). Thrombopoietin: a tumor marker for ovarian cancer
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cases,	when	the	cut-off	level	for	CA-125	was	taken	as	30	U/
mL,	the	sensitivity	was	92%,	specificity	was	76%,	and	NPV	was	
84%.	The	PPV	of	CA-125	was	found	to	be	79%,	when	it	was	
used	as	a	single	marker;	however	it	had	risen	to	85%	when	
both	CA-125	and	thrombopoietin	levels	were	used.	There	was	
only	1	patient	with	normal	CA-125	and	elevated	thrombopoi-
etin	levels	(Table	4).	
The	post-treatment	serum	thrombopoietin	levels	in	the	ma-
lignant	group	were	significantly	lower	as	compared	with	the	
preoperative	thrombopoietin	levels	(p=0.002).	However,	there	
was	no	significant	relationship	between	responders	and	non-
responders	to	treatment	in	terms	of	post-treatment	serum	
thrombopoietin	levels	(p=0.907).	
DISCUSSION
The	reason	for	increased	thrombopoietin	levels	in	cases	with	
invasive	ovarian	cancer	could	be	secondary	to	direct	produc-
tion	from	the	tumoral	tissue	or	certain	other	growth	factors	
that	trigger	thrombopoietin	production	from	the	target	or-
gans	or	to	inflammatory	cytokines.	Studies	that	support	both	
situations	exist	in	the	literature.	Furuhashi	et	al.	[9]	showed	in-
creased	immunohistochemical	expression	of	thrombopoietin	
in	a	case	of	ovarian	cancer.	Torres	et	al.	[13]	and	Chambers	[14]	
found	evidence	in	association	with	the	fact	that	cytokines,	
such	as	IL-6,	IL-10,	CSF-1,	TGF-b,	and	TNF	contribute	to	tumor	
development	in	the	pathogenesis	of	ovarian	cancer.	In	a	study	
that	supports	these	data,	Nowak	et	al.	[15]	compared	the	lev-
els	of	IL-6,	IL-8,	and	IL-10	in	benign	cases,	and	in	early	and	ad-
vanced	stage	ovarian	cancer	cases,	and	concluded	that	these	
cytokines	could	be	useful	in	the	identification	of	malignancy.
The	only	study	that	has	evaluated	the	relation	of	throm-
bopoietin	with	benign	ovarian	cysts	and	ovarian	cancers	
includes	51	invasive	ovarian	cancer	cases	and	25	cases	of	be-
nign	adnexal	masses	[16].	This	study	is	in	agreement	with	our	
study	with	respect	to	serum	preoperative	thrombopoietin	lev-
els,	which	are	reported	to	be	significantly	higher	in	malignant	
cases,	and	with	respect	to	thrombocyte	count	and	thrombo-
poietin	levels,	as	no	relationship	has	been	found	between	the	
two	groups.	Also	in	agreement	to	this	study,	it	has	not	been	
possible	to	show	a	significant	relationship	between	preopera-
tive	serum	thrombopoietin	levels	and	tumor	grade,	ascites	cy-
tology,	presence	of	residual	mass,	and	response	to	treatment.	
However,	an	important	difference	from	Tsukishiro	et	al.	[16]	
is	that	serum	thrombopoietin	levels	are	found	significantly	
higher	in	stage	III-IV	cases	and	cases	with	serous	histology	in	
our	study.	Because	thrombopoietin	is	not	only	a	protein	syn-
thesized	from	ovarian	cancer	cells	and	can	be	influenced	by	
many	physiologic	and	pathologic	situations,	it	does	not	seem	
possible	to	conclude	this	high	level	in	advanced	stage	serous	
histology	cases	can	be	totally	attributed	to	malignancy.	
We	have	also	attempted	to	assess	whether	any	relation	ex-
ists	between	response	to	treatment	and	thrombopoietin	by	
evaluating	serum	levels	following	surgery	and	chemotherapy.	
Although	thrombopoietin	levels	fell	significantly	following	
treatment,	there	was	no	relationship	between	the	patients	
that	responded	and	did	not	respond	to	treatment.	This	post-
operative/post-chemotherapy	decline	is	an	expected	result	
and	this	finding	limits	the	relevance	of	thrombopoietin	in	the	
evaluation	of	response	to	treatment	in	cases	with	ovarian	can-
cer.	
Cost	effectiveness	is	also	calculated	for	thrombopoietin,	
as	it	is	an	important	factor	for	all	screening	tests.	The	cost	of	
thrombopoietin	amounts	to	approximately	9.75$	per	patient	
and	this	is	a	well	price	when	compared	to	other	tools	such	as	
CA-125	and	transvaginal	ultrasonography.	While	CA-125	has	
a	cost	of	6.5$	per	patient,	transvaginal	ultrasonography	has	a	
cost	of	15$.	
In	conclusion,	although	thrombopoietin	can	play	an	additive	
role	for	prediction	of	ovarian	cancer,	it	has	no	superiority	to	
CA-125,	which	is	in	widespread	use.	It	has	also	no	relationship	
with	the	majority	of	prognostic	factors	and	its	significance	in	
the	evaluation	of	‘response	to	treatment’	is	limited.	
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